QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical
Visit exhibit 106 to learn how Covalon is leading the charge with compassion driven innovation through gentler infection prevention solutionsMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX:
--Poster session at ASGCT meeting describes key progress with shielded CD45 cells--CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Nutrien Ltd. (TSX and NYSE: NTR) announced today that Mr. Ken Seitz, Nutrien’s President and Chief Executive Officer, will be speaking at the BMO Farm to Market Conference on Wednesday, May 17 at 8:00 a.m. EDT.
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including
Juno will bring a much-needed expanded offering of critical pharmaceuticals to Canada, by investing in domestic productionTORONTO--(BUSINESS WIRE)--Today, Juno Pharmaceuticals Canada (“Juno”), a leader in the commercialization of specialty pharmaceut
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Mara Renewables Corporation (Mara) is delighted to announce they have made the Sustainable Development Technology Canada (SDTC) Canada’s Sustainability Changemakers list for 2023. The list is comprised of the top t
PARSIPPANY, N.J. & OAKVILLE, Ontario--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin)
Received a positive response from the Canada Revenue Agency (the “CRA”) to our Notices of Objection regarding the Harmonized Sales Tax (“HST”) matter previously disclosed in our financial statements The CRA has provided updated Notices of Reass
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data from first 100 patients at the one-year interim timepoint confirm significant and clinically important, sustained
Dr. Waylon Hunt took an unusual path to co-founding and leading a lab-based business, Intrinsic Analytics.
With a burgeoning scientific portfolio showing a unique ability to boost Akkermansia and Bifidobacteria levels, new products launching before the end of 2023, and international regulatory approvals, Solnul resistant starch “is primed to further penetrate
ElevateIP is a program funded by the Government of Canada aimed at equipping and supporting Canadian start-ups with the tools and knowledge to understand, strategize, protect, manage and leverage their intellectual property (IP)
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.